Phase III randomised studies in non-oncogene-driven NSCLC typically report durable responses in 20%–30% of patients treated with immune checkpoint inhibitors (ICI) targeting PD-1/PD-L1 (1). The gene discussed is CD274; the disease is non-small cell lung carcinoma.